ST1936是一种选择性的纳摩尔亲和力的5-HT6受体激动剂,对人5-HT6、5-HT7和 5-HT2B受体的Ki值分别为 13 nM,168 nM 和 245 nM。ST1936 对人和大鼠的 α2 肾上腺素受体也显示出中等亲和力 (Ki为 300 nM)。
生物活性 | ST1936 is a selective, nanomolar affinity5-HT6receptoragonist withKivalues of 13 nM, 168 nM and 245 nM for human5-HT6, 5-HT7and 5-HT2Breceptors, respectively. ST1936 also shows moderate affinity (Kiof 300 nM) for human and ratα2adrenergic receptor[1]. |
IC50& Target | 5-HT6Receptor 13 nM (Ki) | 5-HT7Receptor 168 nM (Ki) | 5-HT2BReceptor 245 nM (Ki) | α1-adrenergic receptor 390 nM (Ki, rat) | α2-adrenergic receptor 300 nM (Ki, rat) | α2-adrenergic receptor 300 nM (Ki, human) |
|
体外研究 (In Vitro) | ST1936 appears to be relatively selective for 5-HT6receptors, although it has shown affinity also for 5-HT2B, 5-HT1A, 5-HT7receptor and α-adrenergic receptors when tested in a broad crossreactivity panel that comprised G-protein-coupled receptors, ion channel binding sites, enzymes, and transporters[1]. ST1936 behaves as a full 5-HT6agonist on cloned cells and is able to increase Ca2+concentration, phosphorylation of Fyn kinase, and regulate the activation of ERK1/2 that is a downstream target of Fyn kinase[2]. ST1936 reduces the frequency of spontaneous excitatory postsynaptic currents, with an IC50of 1.3 μM[3].
|
体内研究 (In Vivo) | ST1936 (5, 10, 20 mg/kg; i.p.) increases in a dose dependent manner extracellular dopamine (DA) and NA levels in the prefrontal cortex (PFCX)[4]. ST1936 (5, 10, 20 mg/kg; i.p.) increases extracellular DA and NA levels in the nucleus accumbens (NAc) core. Doses of 10 mg/kg increases dialysate DA (peak: 179%) while higher dose increases both DA and NA dialysates (201% and 231%, respectively). Doses of 5 mg/kg does not produce any effect[4].
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 100 mg/mL(422.40 mM;Need ultrasonic) 配制储备液 1 mM | 4.2240 mL | 21.1202 mL | 42.2404 mL | 5 mM | 0.8448 mL | 4.2240 mL | 8.4481 mL | 10 mM | 0.4224 mL | 2.1120 mL | 4.2240 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (10.56 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (10.56 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (10.56 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (10.56 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (10.56 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (10.56 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|